The latest price target for ProKidney (NASDAQ:PROK) was reported by JP Morgan on September 30, 2024. The analyst firm set a price target for $0.00 expecting PROK to fall to within 12 months (a possible -100.00% downside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for ProKidney (NASDAQ:PROK) was provided by JP Morgan, and ProKidney initiated their neutral rating.

There is no last upgrade for ProKidney

The last downgrade for ProKidney Corp happened on January 2, 2024 when B of A Securities changed their price target from $8 to $2 for ProKidney Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ProKidney, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ProKidney was filed on September 30, 2024 so you should expect the next rating to be made available sometime around September 30, 2025.

While ratings are subjective and will change, the latest ProKidney (PROK) rating was a initiated with a price target of $0.00 to $0.00. The current price ProKidney (PROK) is trading at is $1.71, which is out of the analyst’s predicted range.